nach oben

Current Infectious Disease Reports

Erschienen in:

01.02.2012 | HIV/AIDS (RD MacArthur, Section Editor)

HIV/AIDS in Women and Racial/Ethnic Minorities in the U.S.

verfasst von: Valerie E. Stone

Erschienen in: Current Infectious Disease Reports | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

The clinical issues affecting women with HIV/AIDS differ little from those affecting men. However, current research shows that treatment and outcome disparities affect many women with HIV, hypothesized to result from a complex interplay of socioeconomic and gender role influences. These disparities are also a reflection of racial/ethnic differences in treatment and outcome, since 80% of women with HIV/AIDS are black or Hispanic. Women have unique needs for HIV prevention — both prevention of sexual transmission to or from sexual partners and prevention of perinatal transmission. Racial/ethnic minorities continue to be disproportionately affected by the HIV/AIDS epidemic in the U.S. Minorities are less likely to be in care and on HAART than others with HIV/AIDS. These disparities result in poorer outcomes for minorities, especially blacks, with HIV/AIDS. New strategies for optimizing engagement and retention in care, and for prevention hold great promise for women and minorities with HIV in the U.S.

Centers for Disease Control and Prevention. HIV surveillance report, 2009; vol 21, pp. 1–79. http://www.cdc.gov/hiv/topics/surveillance/resources/reports/. Published February 2011. Accessed July 15, 2011.

UNAIDS. Global report: UNAIDS report on the global AIDS epidemic 2010. Available at: http://www.unaids.org/globalreport/Global_report.htm. Accessed on July 23, 2011.

Center for Disease Control and Prevention. HIV slide set: HIV surveillance in women (through 2009). Available at: http://www.cdc.gov/hiv/topics/surveillance/resources/slides/women/index.htm. Accessed on July 23, 2011.

Massachusetts Department of Public Health, Bureau of Infectious Disease, Office of HIV/AIDS. Intersecting risks: HIV infection among heterosexual women and men in Massachusetts. December 1, 2010. Available at: http://www.mass.gov/Eeohhs2/docs/dph/aids/intersecting_risks.pdf. Accessed July 18, 2011.

Center for Disease Control and Prevention. HIV slide set: HIV mortality (through 2007). Available at: http://www.cdc.gov/hiv/topics/surveillance/resources/slides/mortality/index.htm. Accessed on July 23, 2011.

Whitmore SK, Zhang X, Taylor A, Blair J. Estimated number of infants born to HIV-infected women in the United States and five dependent areas, 2006. J Acquir Immune Defic Syndr. 2011;57(3):218–22.PubMedCrossRef

Center for Disease Control and Prevention. Slide set: pediatric HIV/AIDS surveillance (through 2009). Available at: http://www.cdc.gov/hiv/topics/surveillance/resources/slides/pediatric/index.htm. Accessed on July 23, 2011.

•• Panel on Treatment of HIV-infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for the use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal transmission in the United States. Department of Health and Human Services. May 24, 2010; pp. 1–117. Available at: http://www.aidsinfo.nih.gov/ContentFiles/PerinatalGL.pdf. Accessed on July 1, 2011. Updated guidelines for treating pregnant women with HIV. These guidelines provide a comprehensive review of relevant efficacy and toxicity data.

• Moodley D, Esterhuizen T, Pather T, et al. High HIV incidence during pregnancy: compelling reason for repeat HIV testing. AIDS. 2009;23(10):1255–9. Large cohort study showing a high rate of acquisition of HIV during pregnancy which is the basis for both early and late HIV testing during pregnancy. PubMedCrossRef

10.

Heffron R, Donnell D, Rees H, et al. Hormonal contraceptive use and risk of HIV-1 transmission: a prospective cohort analysis. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Rome. July 20, 2011. Abstract # WEAX0206.

11.

Center for Disease Control and Prevention. HIV surveillance by race/ethnicity (through 2009). Available at: http://www.cdc.gov/hiv/topics/surveillance/resources/slides/race-ethnicity/index.htm. Accessed on July 23, 2011.

12.

•• Cargill V, Fenton KA. The epidemiology, prevention, and control of HIV/AIDS among African Americans. In: Stone VE, Ojikutu B, Rawlings MK, Smith KY, editors. HIV/AIDS in US communities of color. New York: Springer; 2009. p. 1–22. This is Chapter 1 in the first comprehensive text book on HIV/AIDS among U.S. racial/ethnic minorities. CrossRef

13.

•• Stone VE. Overcoming challenges to successful treatment outcomes in minority patients with HIV/AIDS. In: Stone VE, Ojikutu B, Rawlings MK, Smith KY, editors. HIV/AIDS in US communities of color. New York: Springer; 2009. p. 53–67. This is Chapter 2 in the first comprehensive text book on HIV/AIDS among U.S. racial/ethnic minorities. CrossRef

14.

The White House Office of National AIDS Policy. National HIV/AIDS strategy for the United States. July 2010. http://www.whitehouse.gov/sites/default/files/uploads/NHAS.pdf. Accessed May 23, 2011.

15.

El-Sadr WM, Mayer KH, Adimora AA. The HIV epidemic in the United States: a time for action. J Acquir Immune Defic Syndr. 2010;55(S2):S63.PubMed

16.

• El Sadr WM, Mayer KH, Hodder SL. AIDS in America: forgotten but not gone. N Engl J Med. 2010;362(11):967–70. Compelling review of the current status of the U.S. HIV/AIDS epidemic and why there is a need for new strategies to address this epidemic. PubMedCrossRef

17.

Center for Disease Control and Prevention. HIV surveillance in injections drug users (through 2009). Available at: http://www.cdc.gov/hiv/idu/resources/slides/index.htm. Accessed on July 23, 2001.

18.

Center for Disease Control and Prevention. HIV surveillance in men who have sex with men. Available at: http://www.cdc.gov/hiv/topics/surveillance/resources/slides/msm/index.htm. Accessed on July 23, 2011.

19.

•• Lemly DC, Shepherd BE, Hulgan T, et al. Race and sex differences in antiretroviral therapy use and mortality among HIV-infected persons in care. J Infect Dis. 2009;199:991–8. Large study showing that minorities and women in care spend less time on HAART and this is associated with poorer longer outcomes. PubMedCrossRef

20.

•• Lillie-Blanton M, Stone VE, Jones AS, et al. Association of race, substance abuse, and health insurance coverage with use of highly active antiretroviral therapy among HIV-infected women, 2005. Am J Public Health. 2010;100:1493–9. This study analyzed a large cohort of women and their care experiences and found that minority, uninsured and/or alcohol using women were more likely to not be receiving HAART. PubMedCrossRef

21.

•• Losina E, Schackman BR, Sadownik SN, et al. Racial and sex disparities in life expectancy losses among HIV-infected persons in the U.S.: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy. Clin Infect Dis. 2009;49:1570–8. Very important study using state transition modeling techniques, which found that women and minorities have lower life expectancy following an HIV diagnosis. PubMedCrossRef

22.

Smith KY. Paying the price for late starts and early stops: racial and sex disparities in HIV-related mortality. Clin Infect Dis. 2009;49:1579–81.PubMedCrossRef

23.

Mugavero MJ, Lin HY, Willig JH, et al. Missed visits and mortality among patients establishing initial outpatient HIV treatment. Clin Infect Dis. 2009;48:248–56.PubMedCrossRef

24.

Fagan JL, Bertolli J, McNaghten AD. Understanding people who have never received HIV medical care: a population based approach. Public Health Reports. 2010;125:520–7.PubMed

25.

Metsch LR, Bell C, Pereyra M, et al. Hospitalized HIV-infected patients in the era of highly active antiretroviral therapy. Am J Public Health. 2009;99:1045–9.PubMedCrossRef

26.

Bell C, Metsch LR, Vogenthaler N, et al. Never in care: characteristics of HIV-infected crack cocaine users in 2 U.S. cities who have never been to HIV care. J Acquir Immune Defic Syndr. 2010;54:376–80.PubMed

27.

Meditz AL, MaWhinney S, Allshouse A, et al. Sex, race and geographic region influence clinical outcomes following primary HIV-1 infection. J Infect Dis. 2011;203:442–51.PubMedCrossRef

28.

Giordano TP, Bartsch G, Zhang Y, et al. Disparities in outcomes for African American and Latino subjects in the Flexible Initial Retrovirus Suppressive Therapies (FIRST) trial. AIDS Patient Care and STDs. 2010;24:287–95.PubMedCrossRef

29.

Currier J, Averitt Bridge D, Hagins D, et al. Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial. Ann Intern Med. 2010;153(6):349–57.PubMed

30.

Smith KY, Garcia F, Ryan R, et al. GRACE (Gender Race and Clinical Experience): outcomes by race at week 48. 49th Interscience Conference on Antimicrobial Agents and Chemotherapeutics (ICAAC), San Francisco, September 12, 2009, Abstract H-918.

31.

• Ribaudo H, Smith KY, Robbins G, et al. Race difference in the efficacy of initial ART on HIV infection in randomized trials undertaken by ACTG. Presented at: 18th Conference on Retroviruses and Opportunistic Infections (CROI 2011); February 27–March 1; Boston, MA. Paper #50. This meta-analysis looks at virologic outcomes on five ACTG trials and found that minorities ahd 40% lower response rates.

32.

• Smith KY, Tierney C, Daar E, et al. Association of race/ethnicity and sex on outcomes in ACTG Study A5202. 18th Conference on Retroviruses and Opportunistic Infections (CROI 2011). Boston, February 27–March 2, 2011. Abstract 536. This study examined a large recent ACTG study, # 5202, and found that minorities did more poorly on all study arms (regimens).

33.

•• Gardner EM, McLees MP, Steiner JF, et al. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis. 2011;52(6):793–800. Very important article which used modeling techniques to estimate levels of engagement of HIV care and estimates of numbers and percentages of U.S. patients at each level. PubMedCrossRef

34.

Lange JM. Test and treat: is it enough? Clin Infect Dis. 2011;52:801–2.PubMedCrossRef

35.

Horstman E, Brown J, Islam F, et al. Retaining HIV-infected patients in care: Where are we? Where do we go from here? Clin Infect Dis. 2010;50:752–61.

36.

Christopoulos KA, Das M, Colfax GN. Linkage and retention in HIV care among men who have sex with men in the U.S. Clin Infect Dis. 2011;52(S2):S214–22.PubMedCrossRef

37.

Smith KY, Aziz M. Challenges and successes in linking HIV-infected women to care in the U.S. Clin Infect Dis. 2011;52(S2):S231–7.PubMed

38.

Mugaavero MJ, Norton WE, Saag MS. Health care system and policy factors influencing engagement in HIV medical care: piecing together the fragments of a fractured health care delivery system. Clin Infect Dis. 2011;52(S2):S238–46.CrossRef

39.

•• Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587–99. The first study to show efficacy of pre-exposure prophylaxis (PrEP) in human subjects, specifically in men who have sex with men. PubMedCrossRef

40.

•• Baeten J, Celum C. Antiretroviral Pre-Exposure Prophylaxis for HIV-1 prevention among heterosexual African men and women: the Partners PrEP Study. 6^th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Rome. July 18, 2011. Abstract #MOAX0106. One of the two initial clinical trials which showed efficacy of pre-exposure prophylaxis (PrEP) in serodiscordant heterosexual couples.

41.

•• Thigpen MC, Kebaabetswe PM, Smith DK, et al. Daily oral antiretroviral use for the prevention of HIV infection in heterosexually active young adults in Botswana: results from the TDF2 study. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Rome. July 18, 2011. Abstract #WELBC01. One of the two initial studies which showed efficacy of pre exposure prophylaxis (PrEP) in serodiscordant heterosexual couples.

Titel: HIV/AIDS in Women and Racial/Ethnic Minorities in the U.S.
verfasst von: Valerie E. Stone
Publikationsdatum: 01.02.2012
Verlag: Current Science Inc.
Erschienen in: Current Infectious Disease Reports / Ausgabe 1/2012
Print ISSN: 1523-3847
Elektronische ISSN: 1534-3146
DOI: https://doi.org/10.1007/s11908-011-0226-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2012

Kidney Disease in HIV-Infected Persons

Update on Cytomegalovirus Infections of the Gastrointestinal System in Solid Organ Transplant Recipients

The Role of Innate Immunity in the Host Defense Against Intestinal Bacterial Pathogens

Diagnosis, Treatment, and Prevention of Anal Cancer

Current Concept in the Pathophysiology of Hepatitis Delta Infection

Key Concepts in the Early Immunology of HIV-1 Infection